Empowering Innovators in Biopharma and Beyond

Join the growing list of organizations achieving their R&D goals with Elucidata.

Real Impact, Real Stories

Case study: Accelerated Target ID using ML-Ready data on Polly
Generative AI Workflow Cuts Regulatory Reporting Time by 4X for Leading RNAi Therapeutics Company
Read More
Case study: Accelerated Target ID using ML-Ready data on Polly
Data-Centric Cross-Species Target Discovery with Polly KG
Read More
Case study: Accelerated Target ID using ML-Ready data on Polly
Polly Knowledge Graph (KG): Co-built, evidence-backed biology for target discovery & validation
Read More

Partnering with Innovators Across Biopharma

Voices of Impact

We were looking for public data on a tight deadline to make decisions on our backup targets for solid tumors. Elucidata was able to understand our relevance criteria, identify, and deliver high-quality harmonized data ahead of schedule.

Ming 'Tommy' Tang
Director of Computational Biology, Immunitas Therapeutics

Elucidata's solutions helped us deepen our understanding of neoantigen-reactive T cells, advancing our T-cell-based anti-tumor therapies. Collaborating with Elucidata enabled crucial insights within six months, offering a clear direction on how to best develop these complex therapeutics

Rubén Alvarez Rodriguez
Head of Research, cTRL Therapeutics

By building a high-quality dataset using harmonized single-cell and bulk RNA-seq data, Elucidata advanced target discovery and lowered preclinical toxicity risks - with results 7× faster than our internal timeline.

HOOKIPA Pharma
South San Francisco

"By streamlining data ingestion, processing, and analysis for AML research, Elucidata eliminated inefficiencies, ensured seamless scalability, and saved $1.34M in compute costs."

US-based cancer diagnostics company
Anonymized at client request

Extremely impressed by Polly and its power to digest and integrate large datasets. The unique partnership that we have allows us to work hand-in-hand with software engineers and scientists to rapidly develop novel hypotheses that we can test in the lab.

Dr. Kate Yen
Founder & CEO, Auron Therapeutics
Why Customers Choose Us

Utilized across 30+ Biopharma, biotech & Diagnostics partners today

3B+

Data points curated in 4 years

25k

Samples curated weekly

200+

Multi-modal data products (>10k samples each) developed

100+

Curators can ingest and label data at once

10X

Acceleration in efficiency

1000+

Hours of data wrangling saved across 20+ curation projects.

They’ve achieved it. So can you!

Let’s Get Started

Request a Demo